Breast Cancer

When used with chemotherapy, pembrolizumab provides a synergistic response to increase survival rates.

Phase 3 monarchE trial assesses distant relapse free-survival, invasive disease-free survival, and overall survival for the treatment of HR-positive/HER2-negative-, node-positive, high-risk early breast cancer.

RxPonder clinical trial results indicate that racial disparities continue to be a major health care challenge.

A new radiation therapy may reduce toxicity compared to standard therapy, paving the way for a safer and possibly, more effective, treatment of early-stage breast cancer.

Results of RIGHT Choice phase 2 clinical trial show Kisqali doubled PFS and showed fewer adverse events.

Pharmacy Times® will be onsite in Texas providing written and video content for the SABCS, which takes place December 6 to 10.

Drs McHayleh and Vinokurov share final thoughts, highlighting the future of treatment for HR+/HER2- breast cancer.

Expert panelists discuss potential coming developments in the treatment landscape for breast cancer.

Data to be presented at the 45th Annual San Antonio Breast Cancer Symposium suggest that the novel sequencing test can detect signs of disease recurrence across breast cancer subtypes, improving outcomes.

Study suggests that high levels of nicotinamide riboside could increase the risk of developing triple-negative breast cancer and may cause the cancer to metastasize to the brain.

Drs Vinokurov and McHayleh discuss how the approach to breast cancer treatment may vary between academic and community health settings.

Drs Vinokurov and McHayleh discuss the impact of clinical trials on the treatment landscape of HR+/HER2- breast cancer.

New system combines computational and experimental techniques to map evolutionary cancer lineages in their natural habitat of human tissue.

Clinical pharmacists play a significant role in treatment management of patients with HR+/HER2- breast cancer.

Drs McHayleh and Vinokurov discuss toxicity management associated with breast cancer treatments.

When it comes to individualized treatment, “we can do better,” said John Edwards, vice president of Healthcare Solutions Consulting at SoftServe.

GDA-501, a novel, genetically modified, nicotinamide natural killer pre-clinical cell therapy.

Study shows there are 2.5 times more breast cancer survivors since the last estimate was conducted in 2007.

Dr McHayleh provides an overview of HR+/HER2- breast cancer treatment strategies and practices.

Alisa Vinokurov, PharmD, and Wassim McHayleh, MD, MBA, FACP, discuss pharmacists’ evolving role in treatment management for breast cancer.

Dr Vinokurov illustrates the evolving role of pharmacists in HR+/HER2- breast cancer treatment.

Wassim McHayleh, MD, MBA, FACP, and Alisa Vinokurov, PharmD, discuss HR+/HER2- breast cancer.

Study finds little evidence to support the long-standing recommendation that women with a first-degree family relative diagnosed with breast cancer should get screened 10 years earlier.

Camizestrant is a next-generation oral SERD and pure Erα antagonist that has demonstrated anti-cancer activity across a range of preclinical models, including in patients with ER-activating mutations.

Results demonstrate improved progression-free survival in the overall patient population and in a prespecified biomarker subgroup of tumors with alterations in specific genes, AstraZeneca says.

By 2019, lung cancer mortality rates decreased by 5.4% in males since 2015, while deaths from ovary cancer have also declined rapidly over the past 2 decades.

Completing a breast cancer-focused continuing education credit and encouraging screenings are 2 ways that pharmacists can get involved during the month of October.

Further, the survey showed that fewer than half of women would flag redness of the breast, thickening of the skin, or 1 breast feeling warmer and heavier than the other as possible symptoms.

Presenters at the AMCP Nexus conference explore outcomes data and whether these medications should be substituted for reference products more frequently.

New agents can offer a more tailored approach to therapy selection.